Opinion of the Transparency Council – docetaxel
At its meeting on 24 February 2025, the Transparency Council adopted opinion No. 35/2025 on the reimbursement of medicines containing the active substance docetaxel for indications of use or dosages or methods of administration that differ from those stated in the Summary of Product Characteristics, i.e. malignant tumor of the esophagus (ICD-10: C15)